Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $4.80.
KPTI has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th.
Check Out Our Latest Stock Analysis on Karyopharm Therapeutics
Institutional Trading of Karyopharm Therapeutics
Karyopharm Therapeutics Stock Performance
Shares of KPTI opened at $0.74 on Tuesday. The firm has a market cap of $91.97 million, a PE ratio of -0.58 and a beta of 0.20. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95. The business’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $1.03.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. Research analysts predict that Karyopharm Therapeutics will post -0.93 EPS for the current fiscal year.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Featured Stories
- Five stocks we like better than Karyopharm Therapeutics
- How to Invest in the Best Canadian Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 9/16 – 9/20
- Best Stocks Under $5.00
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.